Challenge
An established mid-sized pharmaceutical company, with a B2B business model, had initiated the development of a new therapeutic molecule and was seeking to validate market interest and identify potential partners capable of supporting its development and commercialization.
The company needed a structured approach to understand which segments of the pharmaceutical industry could benefit most from the program and to identify partners with the scientific, regulatory, and commercial capabilities required to bring the molecule to market.
BioNext Approach
BioNext supported the client with both strategic and operational expertise. First, we conducted a market intelligence assessment to identify the most relevant industry segments where the molecule could generate the highest value. Based on this analysis, we mapped and screened more than 150 pharmaceutical companies worldwide, evaluating their therapeutic focus, strategic fit, and partnership potential. From this initial universe, 60 companies were prioritized as relevant targets for engagement.
BioNext then supported the preparation of the strategic narrative and outreach strategy, directly engaging selected companies to introduce the development program and explore potential collaboration opportunities.
Outcome
The process enabled the client to validate market interest in the program and identify a shortlist of high-potential strategic partners. Several collaboration discussions were initiated, strengthening the companyˇs partnering strategy and pathway to market.
In addition, the analysis highlighted important differences in pricing dynamics and market access between the US and European markets, providing valuable insight for the future commercialization strategy.